Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models

Most anti-angiogenic therapies currently being evaluated in clinical trials target vascular endothelial growth factor (VEGF) pathway, however, the tumor vasculature can acquire resistance to VEGF-targeted therapy by shifting to other angiogenesis mechanisms. Therefore, other potential therapeutic ag...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Xiao Yu, Xu, Hao, Wu, Zhen Feng, Chen, Che, Liu, Jia Yun, Wu, Guan Nan, Yao, Xue Quan, Liu, Fu Kun, Li, Gang, Shen, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792576/
https://www.ncbi.nlm.nih.gov/pubmed/26575424

Ejemplares similares

Ejemplares similares